Skip to main content
Top
Published in: Abdominal Radiology 7/2016

01-07-2016 | Invited article

Non-focal liver signal abnormalities on hepatobiliary phase of gadoxetate disodium-enhanced MR imaging: a review and differential diagnosis

Authors: Alessandro Furlan, Amir A. Borhani, Matthew T. Heller, Robinson K. Yu, Mitchell E. Tublin

Published in: Abdominal Radiology | Issue 7/2016

Login to get access

Abstract

Gadoxetate disodium (Gd-EOB-DTPA) is a linear, non-ionic paramagnetic MR contrast agent with combined extracellular and hepatobiliary properties commonly used for several liver indications. Although gadoxetate disodium is commonly used for detection and characterization of focal lesions, a spectrum of diffuse disease processes can affect the hepatobiliary phase of imaging (i.e., when contrast accumulates within the hepatocytes). Non-focal signal abnormalities during the hepatobiliary phase can be seen with multiple disease processes such as deposition disorders, infiltrating tumors, vascular diseases, and post-treatment changes. The purpose of this paper is to review the different processes which result in non-focal signal alteration during the hepatobiliary phase and to describe imaging patterns that may order a differential diagnosis and facilitate patient management.
Literature
1.
go back to reference Guglielmo FF, Mitchell DG, Gupta S (2014) Gadolinium contrast agent selection and optimal use for body MR imaging. Radiol Clin N Am 52:637–656CrossRefPubMed Guglielmo FF, Mitchell DG, Gupta S (2014) Gadolinium contrast agent selection and optimal use for body MR imaging. Radiol Clin N Am 52:637–656CrossRefPubMed
2.
go back to reference Hamm B, Staks T, Muhler A, et al. (1995) Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195:785–792CrossRefPubMed Hamm B, Staks T, Muhler A, et al. (1995) Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195:785–792CrossRefPubMed
3.
go back to reference Suh CH, Kim KW, Kim GY, et al. (2015) The diagnostic value of Gd-EOB-DTPA-MRI for the diagnosis of focal nodular hyperplasia: a systematic review and meta-analysis. Eur Radiol 25:950–960CrossRefPubMed Suh CH, Kim KW, Kim GY, et al. (2015) The diagnostic value of Gd-EOB-DTPA-MRI for the diagnosis of focal nodular hyperplasia: a systematic review and meta-analysis. Eur Radiol 25:950–960CrossRefPubMed
4.
go back to reference Ba-Ssalamah A, Antunes C, Feier D, et al. (2015) Morphologic and molecular features of hepatocellular adenoma with gadoxetic acid-enhanced MR imaging. Radiology 277:104–113CrossRefPubMed Ba-Ssalamah A, Antunes C, Feier D, et al. (2015) Morphologic and molecular features of hepatocellular adenoma with gadoxetic acid-enhanced MR imaging. Radiology 277:104–113CrossRefPubMed
5.
go back to reference Kim HJ, Lee SS, Byun JH, et al. (2015) Incremental value of liver MR imaging in patients with potentially curable colorectal hepatic metastasis detected at CT: a prospective comparison of diffusion-weighted imaging, gadoxetic acid-enhanced MR imaging, and a combination of both MR techniques. Radiology 274:712–722CrossRefPubMed Kim HJ, Lee SS, Byun JH, et al. (2015) Incremental value of liver MR imaging in patients with potentially curable colorectal hepatic metastasis detected at CT: a prospective comparison of diffusion-weighted imaging, gadoxetic acid-enhanced MR imaging, and a combination of both MR techniques. Radiology 274:712–722CrossRefPubMed
6.
go back to reference Merkle EM, Zech CJ, Bartolozzi C, et al. (2016) Consensus report from the 7th international forum for liver magnetic resonance imaging. Eur Radiol 26:674–682CrossRefPubMed Merkle EM, Zech CJ, Bartolozzi C, et al. (2016) Consensus report from the 7th international forum for liver magnetic resonance imaging. Eur Radiol 26:674–682CrossRefPubMed
7.
go back to reference Hope TA, Fowler KJ, Sirlin CB, et al. (2015) Hepatobiliary agents and their role in LI-RADS. Abdom Imaging 40:613–625CrossRefPubMed Hope TA, Fowler KJ, Sirlin CB, et al. (2015) Hepatobiliary agents and their role in LI-RADS. Abdom Imaging 40:613–625CrossRefPubMed
8.
go back to reference Costa EA, Cunha GM, Smorodinsky E, et al. (2015) Diagnostic accuracy of preoperative gadoxetic acid-enhanced 3-T MR imaging for malignant liver lesions by using ex vivo MR imaging-matched pathologic findings as the reference standard. Radiology 276:775–786CrossRefPubMed Costa EA, Cunha GM, Smorodinsky E, et al. (2015) Diagnostic accuracy of preoperative gadoxetic acid-enhanced 3-T MR imaging for malignant liver lesions by using ex vivo MR imaging-matched pathologic findings as the reference standard. Radiology 276:775–786CrossRefPubMed
9.
go back to reference Chen N, Motosugi U, Morisaka H, et al. (2016) Added value of gadoxetic acid-enhanced hepatocyte-phase image to the LI-RADS system for diagnosis of hepatocellular carcinoma. Magn Reson Med Sci 15:49–59CrossRefPubMed Chen N, Motosugi U, Morisaka H, et al. (2016) Added value of gadoxetic acid-enhanced hepatocyte-phase image to the LI-RADS system for diagnosis of hepatocellular carcinoma. Magn Reson Med Sci 15:49–59CrossRefPubMed
10.
go back to reference Lee NK, Kim S, Lee JW, et al. (2009) Biliary MR imaging with Gd-EOB-DTPA and its clinical applications. Radiographics 29:1707–1724CrossRefPubMed Lee NK, Kim S, Lee JW, et al. (2009) Biliary MR imaging with Gd-EOB-DTPA and its clinical applications. Radiographics 29:1707–1724CrossRefPubMed
11.
go back to reference Besa C, Bane O, Jajamovich G, Marchione J, Taouli B (2015) 3D T1 relaxometry pre and post gadoxetic acid injection for the assessment of liver cirrhosis and liver function. Magn Reson Imaging 33:1075–1082CrossRefPubMed Besa C, Bane O, Jajamovich G, Marchione J, Taouli B (2015) 3D T1 relaxometry pre and post gadoxetic acid injection for the assessment of liver cirrhosis and liver function. Magn Reson Imaging 33:1075–1082CrossRefPubMed
12.
go back to reference Goshima S, Kanematsu M, Watanabe H, et al. (2012) Gd-EOB-DTPA-enhanced MR imaging: prediction of hepatic fibrosis stages using liver contrast enhancement index and liver-to-spleen volumetric ratio. J Magn Reson Imaging 36:1148–1153CrossRefPubMed Goshima S, Kanematsu M, Watanabe H, et al. (2012) Gd-EOB-DTPA-enhanced MR imaging: prediction of hepatic fibrosis stages using liver contrast enhancement index and liver-to-spleen volumetric ratio. J Magn Reson Imaging 36:1148–1153CrossRefPubMed
13.
go back to reference Wibmer A, Aliya Q, Steiniger R, et al. (2012) Liver transplantation: impaired biliary excretion of gadoxate is associated with an inferior 1-year retransplantation-free survival. Invest Radiol 47:353–358CrossRefPubMed Wibmer A, Aliya Q, Steiniger R, et al. (2012) Liver transplantation: impaired biliary excretion of gadoxate is associated with an inferior 1-year retransplantation-free survival. Invest Radiol 47:353–358CrossRefPubMed
15.
go back to reference Jhaveri K, Cleary S, Audet P, et al. (2015) Consensus statements from a multidisciplinary expert panel on the utilization and application of a liver-specific MRI contrast agent (gadoxetic acid). AJR Am J Roentgenol 204:498–509CrossRefPubMed Jhaveri K, Cleary S, Audet P, et al. (2015) Consensus statements from a multidisciplinary expert panel on the utilization and application of a liver-specific MRI contrast agent (gadoxetic acid). AJR Am J Roentgenol 204:498–509CrossRefPubMed
16.
go back to reference Ringe KI, Husarik DB, Sirlin CB, Merkle EM (2010) Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol 195:13–28CrossRefPubMed Ringe KI, Husarik DB, Sirlin CB, Merkle EM (2010) Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol 195:13–28CrossRefPubMed
17.
go back to reference Esterson YB, Flusberg M, Oh S, et al. (2015) Improved parenchymal liver enhancement with extended delay on Gd-EOB-DTPA-enhanced MRI in patients with parenchymal liver disease: associated clinical and imaging factors. Clin Radiol 70:723–729CrossRefPubMed Esterson YB, Flusberg M, Oh S, et al. (2015) Improved parenchymal liver enhancement with extended delay on Gd-EOB-DTPA-enhanced MRI in patients with parenchymal liver disease: associated clinical and imaging factors. Clin Radiol 70:723–729CrossRefPubMed
18.
go back to reference Tschirch FT, Struwe A, Petrowsky H, et al. (2008) Contrast-enhanced MR cholangiography with Gd-EOB-DTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchyma. Eur Radiol 18:1577–1586CrossRefPubMed Tschirch FT, Struwe A, Petrowsky H, et al. (2008) Contrast-enhanced MR cholangiography with Gd-EOB-DTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchyma. Eur Radiol 18:1577–1586CrossRefPubMed
19.
go back to reference Motosugi U, Ichikawa T, Tominaga L, et al. (2009) Delay before the hepatocyte phase of Gd-EOB-DTPA-enhanced MR imaging: is it possible to shorten the examination time? Eur Radiol 19:2623–2629CrossRefPubMed Motosugi U, Ichikawa T, Tominaga L, et al. (2009) Delay before the hepatocyte phase of Gd-EOB-DTPA-enhanced MR imaging: is it possible to shorten the examination time? Eur Radiol 19:2623–2629CrossRefPubMed
20.
go back to reference Leonhardt M, Keiser M, Oswald S, et al. (2010) Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab Dispos 38:1024–1028CrossRefPubMed Leonhardt M, Keiser M, Oswald S, et al. (2010) Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab Dispos 38:1024–1028CrossRefPubMed
21.
go back to reference Nassif A, Jia J, Keiser M, et al. (2012) Visualization of hepatic uptake transporter function in healthy subjects by using gadoxetic acid-enhanced MR imaging. Radiology 264:741–750CrossRefPubMed Nassif A, Jia J, Keiser M, et al. (2012) Visualization of hepatic uptake transporter function in healthy subjects by using gadoxetic acid-enhanced MR imaging. Radiology 264:741–750CrossRefPubMed
22.
go back to reference Schwope RB, May LA, Reiter MJ, Lisanti CJ, Margolis DJ (2015) Gadoxetic acid: pearls and pitfalls. Abdom Imaging 40:2012–2029CrossRefPubMed Schwope RB, May LA, Reiter MJ, Lisanti CJ, Margolis DJ (2015) Gadoxetic acid: pearls and pitfalls. Abdom Imaging 40:2012–2029CrossRefPubMed
23.
go back to reference Yoneda N, Matsui O, Ikeno H, et al. (2015) Correlation between Gd-EOB-DTPA-enhanced MR imaging findings and OATP1B3 expression in chemotherapy-associated sinusoidal obstruction syndrome. Abdom Imaging 40:3099–3103CrossRefPubMed Yoneda N, Matsui O, Ikeno H, et al. (2015) Correlation between Gd-EOB-DTPA-enhanced MR imaging findings and OATP1B3 expression in chemotherapy-associated sinusoidal obstruction syndrome. Abdom Imaging 40:3099–3103CrossRefPubMed
24.
go back to reference Kitao A, Zen Y, Matsui O, et al. (2010) Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR imaging—correlation with molecular transporters and histopathologic features. Radiology 256:817–826CrossRefPubMed Kitao A, Zen Y, Matsui O, et al. (2010) Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR imaging—correlation with molecular transporters and histopathologic features. Radiology 256:817–826CrossRefPubMed
25.
go back to reference Kitao A, Matsui O, Yoneda N, et al. (2011) The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol 21:2056–2066CrossRefPubMed Kitao A, Matsui O, Yoneda N, et al. (2011) The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol 21:2056–2066CrossRefPubMed
26.
go back to reference Narita M, Hatano E, Arizono S, et al. (2009) Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 44:793–798CrossRefPubMed Narita M, Hatano E, Arizono S, et al. (2009) Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 44:793–798CrossRefPubMed
27.
go back to reference Verloh N, Haimerl M, Rennert J, et al. (2013) Impact of liver cirrhosis on liver enhancement at Gd-EOB-DTPA enhanced MRI at 3 Tesla. Eur J Radiol 82:1710–1715CrossRefPubMed Verloh N, Haimerl M, Rennert J, et al. (2013) Impact of liver cirrhosis on liver enhancement at Gd-EOB-DTPA enhanced MRI at 3 Tesla. Eur J Radiol 82:1710–1715CrossRefPubMed
28.
go back to reference Kang Y, Lee JM, Kim SH, Han JK, Choi BI (2012) Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images. Radiology 264:751–760CrossRefPubMed Kang Y, Lee JM, Kim SH, Han JK, Choi BI (2012) Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images. Radiology 264:751–760CrossRefPubMed
29.
go back to reference Poynard T, Mathurin P, Lai CL, et al. (2003) A comparison of fibrosis progression in chronic liver diseases. J Hepatol 38:257–265CrossRefPubMed Poynard T, Mathurin P, Lai CL, et al. (2003) A comparison of fibrosis progression in chronic liver diseases. J Hepatol 38:257–265CrossRefPubMed
31.
go back to reference Ito K, Mitchell DG, Siegelman ES (2002) Cirrhosis: MR imaging features. Magn Reson Imaging Clin N Am 10:75–92CrossRefPubMed Ito K, Mitchell DG, Siegelman ES (2002) Cirrhosis: MR imaging features. Magn Reson Imaging Clin N Am 10:75–92CrossRefPubMed
32.
go back to reference Brancatelli G, Federle MP, Ambrosini R, et al. (2007) Cirrhosis: CT and MR imaging evaluation. Eur J Radiol 61:57–69CrossRefPubMed Brancatelli G, Federle MP, Ambrosini R, et al. (2007) Cirrhosis: CT and MR imaging evaluation. Eur J Radiol 61:57–69CrossRefPubMed
33.
go back to reference Faria SC, Ganesan K, Mwangi I, et al. (2009) MR imaging of liver fibrosis: current state of the art. Radiographics 29:1615–1635CrossRefPubMed Faria SC, Ganesan K, Mwangi I, et al. (2009) MR imaging of liver fibrosis: current state of the art. Radiographics 29:1615–1635CrossRefPubMed
34.
go back to reference Park YS, Lee CH, Kim BH, et al. (2013) Using Gd-EOB-DTPA-enhanced 3-T MRI for the differentiation of infiltrative hepatocellular carcinoma and focal confluent fibrosis in liver cirrhosis. Magn Reson Imaging 31(7):1137–1142CrossRefPubMed Park YS, Lee CH, Kim BH, et al. (2013) Using Gd-EOB-DTPA-enhanced 3-T MRI for the differentiation of infiltrative hepatocellular carcinoma and focal confluent fibrosis in liver cirrhosis. Magn Reson Imaging 31(7):1137–1142CrossRefPubMed
35.
go back to reference Lazo M, Hernaez R, Eberhardt MS, et al. (2013) Prevalence of nonalcoholic fatty liver disease in the United States: the third national health and nutrition examination survey, 1988–1994. Am J Epidemiol 178:38–45CrossRefPubMedPubMedCentral Lazo M, Hernaez R, Eberhardt MS, et al. (2013) Prevalence of nonalcoholic fatty liver disease in the United States: the third national health and nutrition examination survey, 1988–1994. Am J Epidemiol 178:38–45CrossRefPubMedPubMedCentral
36.
go back to reference Hamer OW, Aguirre DA, Casola G, et al. (2006) Fatty liver: imaging patterns and pitfalls. Radiographics 26:1637–1653CrossRefPubMed Hamer OW, Aguirre DA, Casola G, et al. (2006) Fatty liver: imaging patterns and pitfalls. Radiographics 26:1637–1653CrossRefPubMed
37.
go back to reference Yeom SK, Byun JH, Kim HJ, et al. (2013) Focal fat deposition at liver MRI with gadobenate dimeglumine and gadoxetic acid: quantitative and qualitative analysis. Magn Reson Imaging 31:911–917CrossRefPubMed Yeom SK, Byun JH, Kim HJ, et al. (2013) Focal fat deposition at liver MRI with gadobenate dimeglumine and gadoxetic acid: quantitative and qualitative analysis. Magn Reson Imaging 31:911–917CrossRefPubMed
38.
go back to reference Onishi H, Theisen D, Dietrich O, Reiser MF, Zech CJ (2014) Hepatic steatosis: effect on hepatocyte enhancement with gadoxetate disodium-enhanced liver MR imaging. J Magn Reson Imaging 39:42–50CrossRefPubMed Onishi H, Theisen D, Dietrich O, Reiser MF, Zech CJ (2014) Hepatic steatosis: effect on hepatocyte enhancement with gadoxetate disodium-enhanced liver MR imaging. J Magn Reson Imaging 39:42–50CrossRefPubMed
39.
go back to reference Bastati N, Feier D, Wibmer A, et al. (2014) Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid-enhanced MR imaging in patients with nonalcoholic fatty liver disease: a proof-of-concept study. Radiology 271:739–747CrossRefPubMed Bastati N, Feier D, Wibmer A, et al. (2014) Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid-enhanced MR imaging in patients with nonalcoholic fatty liver disease: a proof-of-concept study. Radiology 271:739–747CrossRefPubMed
41.
go back to reference Hino K, Nishina S, Hara Y (2013) Iron metabolic disorder in chronic hepatitis C: mechanisms and relevance to hepatocarcinogenesis. J Gastroenterol Hepatol 4:93–98CrossRef Hino K, Nishina S, Hara Y (2013) Iron metabolic disorder in chronic hepatitis C: mechanisms and relevance to hepatocarcinogenesis. J Gastroenterol Hepatol 4:93–98CrossRef
42.
go back to reference Hernando D, Levin YS, Sirlin CB, Reeder SB (2014) Quantification of liver iron with MRI: state of the art and remaining challenges. J Magn Reson Imaging 40:1003–1021CrossRefPubMedPubMedCentral Hernando D, Levin YS, Sirlin CB, Reeder SB (2014) Quantification of liver iron with MRI: state of the art and remaining challenges. J Magn Reson Imaging 40:1003–1021CrossRefPubMedPubMedCentral
44.
go back to reference Bruix J, Sherman M, American Association for the Study of Liver Disease (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022CrossRefPubMedPubMedCentral Bruix J, Sherman M, American Association for the Study of Liver Disease (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022CrossRefPubMedPubMedCentral
46.
go back to reference Asayama Y, Tajima T, Nishie A, et al. (2011) Uptake of Gd-EOB-DTPA by hepatocellular carcinoma: radiologic-pathologic correlation with special reference to bile production. Eur J Radiol 80:e243–e248CrossRefPubMed Asayama Y, Tajima T, Nishie A, et al. (2011) Uptake of Gd-EOB-DTPA by hepatocellular carcinoma: radiologic-pathologic correlation with special reference to bile production. Eur J Radiol 80:e243–e248CrossRefPubMed
47.
go back to reference Kim JY, Kim MJ, Kim KA, Jeong HT, Park YN (2012) Hyperintense HCC on hepatobiliary phase images of gadoxetic acid-enhanced MRI: correlation with clinical and pathological features. Eur J Radiol 81:3877–3882CrossRefPubMed Kim JY, Kim MJ, Kim KA, Jeong HT, Park YN (2012) Hyperintense HCC on hepatobiliary phase images of gadoxetic acid-enhanced MRI: correlation with clinical and pathological features. Eur J Radiol 81:3877–3882CrossRefPubMed
48.
go back to reference Suh YJ, Kim MJ, Choi JY, et al. (2011) Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI. AJR Am J Roentgenol 197:W44–W52CrossRefPubMed Suh YJ, Kim MJ, Choi JY, et al. (2011) Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI. AJR Am J Roentgenol 197:W44–W52CrossRefPubMed
49.
50.
go back to reference Kneuertz PJ, Demirjian A, Firoozmand A, et al. (2012) Diffuse infiltrative hepatocellular carcinoma: assessment of presentation, treatment, and outcomes. Ann Surg Oncol 19:2897–2907CrossRefPubMedPubMedCentral Kneuertz PJ, Demirjian A, Firoozmand A, et al. (2012) Diffuse infiltrative hepatocellular carcinoma: assessment of presentation, treatment, and outcomes. Ann Surg Oncol 19:2897–2907CrossRefPubMedPubMedCentral
51.
go back to reference Reynolds AR, Furlan A, Fetzer DT, et al. (2015) Infiltrative hepatocellular carcinoma: what radiologists need to know. Radiographics 35:371–386CrossRefPubMed Reynolds AR, Furlan A, Fetzer DT, et al. (2015) Infiltrative hepatocellular carcinoma: what radiologists need to know. Radiographics 35:371–386CrossRefPubMed
52.
go back to reference Rosenkrantz AB, Lee L, Matza BW, Kim S (2012) Infiltrative hepatocellular carcinoma: comparison of MRI sequences for lesion conspicuity. Clin Radiol 67:e105–e111CrossRefPubMed Rosenkrantz AB, Lee L, Matza BW, Kim S (2012) Infiltrative hepatocellular carcinoma: comparison of MRI sequences for lesion conspicuity. Clin Radiol 67:e105–e111CrossRefPubMed
53.
go back to reference Lim S, Kim YK, Park HJ, et al. (2014) Infiltrative hepatocellular carcinoma on gadoxetic acid-enhanced and diffusion-weighted MRI at 3.0T. J Magn Reson Imaging 39:1238–1245CrossRefPubMed Lim S, Kim YK, Park HJ, et al. (2014) Infiltrative hepatocellular carcinoma on gadoxetic acid-enhanced and diffusion-weighted MRI at 3.0T. J Magn Reson Imaging 39:1238–1245CrossRefPubMed
54.
go back to reference Chung YE, Kim MJ, Park YN, et al. (2009) Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. Radiographics 29:683–700CrossRefPubMed Chung YE, Kim MJ, Park YN, et al. (2009) Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. Radiographics 29:683–700CrossRefPubMed
55.
go back to reference Jeong HT, Kim MJ, Chung YE, et al. (2013) Gadoxetate disodium-enhanced MRI of mass-forming intrahepatic cholangiocarcinomas: imaging-histologic correlation. AJR Am J Roentgenol 201:W603–W611CrossRefPubMed Jeong HT, Kim MJ, Chung YE, et al. (2013) Gadoxetate disodium-enhanced MRI of mass-forming intrahepatic cholangiocarcinomas: imaging-histologic correlation. AJR Am J Roentgenol 201:W603–W611CrossRefPubMed
56.
go back to reference Koh J, Chung YE, Nahm JH, et al. (2016) Intrahepatic mass-forming cholangiocarcinoma: prognostic value of preoperative gadoxetic acid-enhanced MRI. Eur Radiol 26:407–416CrossRefPubMed Koh J, Chung YE, Nahm JH, et al. (2016) Intrahepatic mass-forming cholangiocarcinoma: prognostic value of preoperative gadoxetic acid-enhanced MRI. Eur Radiol 26:407–416CrossRefPubMed
57.
go back to reference Glimelius B, Oliveira J, ESMO Guidelines Working Group (2009) Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):54–56PubMed Glimelius B, Oliveira J, ESMO Guidelines Working Group (2009) Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):54–56PubMed
58.
go back to reference Danet I, Semelka RC, Leonardou P, et al. (2003) Spectrum of MRI appearances of untreated metastases of the liver. AJR Am J Roentgenol 181:809–817CrossRefPubMed Danet I, Semelka RC, Leonardou P, et al. (2003) Spectrum of MRI appearances of untreated metastases of the liver. AJR Am J Roentgenol 181:809–817CrossRefPubMed
59.
go back to reference Kim A, Lee CH, Kim BH, et al. (2012) Gadoxetic acid-enhanced 3.0T MRI for the evaluation of hepatic metastasis from colorectal cancer: metastasis is not always seen as a “defect” on the hepatobiliary phase. Eur J Radiol 81:3998–4004CrossRefPubMed Kim A, Lee CH, Kim BH, et al. (2012) Gadoxetic acid-enhanced 3.0T MRI for the evaluation of hepatic metastasis from colorectal cancer: metastasis is not always seen as a “defect” on the hepatobiliary phase. Eur J Radiol 81:3998–4004CrossRefPubMed
60.
go back to reference Granata V, Catalano O, Fusco R, et al. (2015) The target sign in colorectal liver metastases: an atypical Gd-EOB-DTPA “uptake” on the hepatobiliary phase of MR imaging. Abdom Imaging 40:2364–2371CrossRefPubMed Granata V, Catalano O, Fusco R, et al. (2015) The target sign in colorectal liver metastases: an atypical Gd-EOB-DTPA “uptake” on the hepatobiliary phase of MR imaging. Abdom Imaging 40:2364–2371CrossRefPubMed
61.
go back to reference Montero JL, Muntane J, de las Heras S, et al. (2002) Acute liver failure caused by diffuse hepatic melanoma infiltration. J Hepatol 37:540–541CrossRefPubMed Montero JL, Muntane J, de las Heras S, et al. (2002) Acute liver failure caused by diffuse hepatic melanoma infiltration. J Hepatol 37:540–541CrossRefPubMed
62.
go back to reference Allison KH, Fligner CL, Parks WT (2004) Radiographically occult, diffuse intrasinusoidal hepatic metastases from primary breast carcinomas: a clinicopathologic study of 3 autopsy cases. Arch Pathol Lab Med 128:1418–1423PubMed Allison KH, Fligner CL, Parks WT (2004) Radiographically occult, diffuse intrasinusoidal hepatic metastases from primary breast carcinomas: a clinicopathologic study of 3 autopsy cases. Arch Pathol Lab Med 128:1418–1423PubMed
63.
go back to reference Rich NE, Sanders C, Hughes RS, et al. (2015) Malignant infiltration of the liver presenting as acute liver failure. Clin Gastroenterol Hepatol 13:1025–1028CrossRefPubMed Rich NE, Sanders C, Hughes RS, et al. (2015) Malignant infiltration of the liver presenting as acute liver failure. Clin Gastroenterol Hepatol 13:1025–1028CrossRefPubMed
64.
go back to reference Sass DA, Clark K, Grzybicki D, Rabinovitz M, Shaw-Stiffel TA (2007) Diffuse desmoplastic metastatic breast cancer simulating cirrhosis with severe portal hypertension: a case of “pseudocirrhosis”. Dig Dis Sci 52:749–752CrossRefPubMed Sass DA, Clark K, Grzybicki D, Rabinovitz M, Shaw-Stiffel TA (2007) Diffuse desmoplastic metastatic breast cancer simulating cirrhosis with severe portal hypertension: a case of “pseudocirrhosis”. Dig Dis Sci 52:749–752CrossRefPubMed
65.
go back to reference Nascimento AB, Mitchell DG, Rubin R, Weaver E (2001) Diffuse desmoplastic breast carcinoma metastases to the liver simulating cirrhosis at MR imaging: report of two cases. Radiology 221:117–121CrossRefPubMed Nascimento AB, Mitchell DG, Rubin R, Weaver E (2001) Diffuse desmoplastic breast carcinoma metastases to the liver simulating cirrhosis at MR imaging: report of two cases. Radiology 221:117–121CrossRefPubMed
66.
go back to reference Young ST, Paulson EK, Washington K, et al. (1994) CT of the liver in patients with metastatic breast carcinoma treated by chemotherapy: findings simulating cirrhosis. AJR Am J Roentgenol 163:1385–1388CrossRefPubMed Young ST, Paulson EK, Washington K, et al. (1994) CT of the liver in patients with metastatic breast carcinoma treated by chemotherapy: findings simulating cirrhosis. AJR Am J Roentgenol 163:1385–1388CrossRefPubMed
67.
go back to reference Tang TJ, Batts KP, de Groen PC, et al. (2001) The prognostic value of histology in the assessment of patients with Budd–Chiari syndrome. J Hepatol 35:338–343CrossRefPubMed Tang TJ, Batts KP, de Groen PC, et al. (2001) The prognostic value of histology in the assessment of patients with Budd–Chiari syndrome. J Hepatol 35:338–343CrossRefPubMed
68.
go back to reference Kitajima K, Yoshikawa T, Seo Y, et al. (2011) A case of Budd–Chiari syndrome: Gd-EOB-DTPA-enhanced MR findings. Magn Reson Imaging 29:579–583CrossRefPubMed Kitajima K, Yoshikawa T, Seo Y, et al. (2011) A case of Budd–Chiari syndrome: Gd-EOB-DTPA-enhanced MR findings. Magn Reson Imaging 29:579–583CrossRefPubMed
70.
go back to reference Rubbia-Brandt L, Lauwers GY, Wang H, et al. (2010) Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 56:430–439CrossRefPubMed Rubbia-Brandt L, Lauwers GY, Wang H, et al. (2010) Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 56:430–439CrossRefPubMed
71.
go back to reference Nakano H, Oussoultzoglou E, Rosso E, et al. (2008) Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247:118–124CrossRefPubMed Nakano H, Oussoultzoglou E, Rosso E, et al. (2008) Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247:118–124CrossRefPubMed
72.
go back to reference Shin NY, Kim MJ, Lim JS, et al. (2012) Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases. Eur Radiol 22(4):864–871CrossRefPubMed Shin NY, Kim MJ, Lim JS, et al. (2012) Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases. Eur Radiol 22(4):864–871CrossRefPubMed
73.
go back to reference Han NY, Park BJ, Sung DJ, et al. (2014) Chemotherapy-induced focal hepatopathy in patients with gastrointestinal malignancy: gadoxetic acid-enhanced and diffusion-weighted MR imaging with clinical-pathologic correlation. Radiology 271:416–425CrossRefPubMed Han NY, Park BJ, Sung DJ, et al. (2014) Chemotherapy-induced focal hepatopathy in patients with gastrointestinal malignancy: gadoxetic acid-enhanced and diffusion-weighted MR imaging with clinical-pathologic correlation. Radiology 271:416–425CrossRefPubMed
74.
go back to reference Giovine S, Pinto A, Crispano S, Lassandro F, Romano L (2006) Retrospective study of 23 cases of hepatic infarction: CT findings and pathological correlations. Radiol Med 111:11–21CrossRefPubMed Giovine S, Pinto A, Crispano S, Lassandro F, Romano L (2006) Retrospective study of 23 cases of hepatic infarction: CT findings and pathological correlations. Radiol Med 111:11–21CrossRefPubMed
75.
go back to reference Maruyama M, Yamada A, Kuraishi Y, et al. (2014) Hepatic infarction complicated with acute pancreatitis precisely diagnosed with gadoxetate disodium-enhanced magnetic resonance imaging. Intern Med 53:2215–2221CrossRefPubMed Maruyama M, Yamada A, Kuraishi Y, et al. (2014) Hepatic infarction complicated with acute pancreatitis precisely diagnosed with gadoxetate disodium-enhanced magnetic resonance imaging. Intern Med 53:2215–2221CrossRefPubMed
76.
go back to reference Livraghi T, Makisako H, Line PD (2011) Treatment options in hepatocellular carcinoma today 100:22–29 Livraghi T, Makisako H, Line PD (2011) Treatment options in hepatocellular carcinoma today 100:22–29
77.
go back to reference Xiao YD, Paudel R, Liu H, et al. (2015) Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging: a potential utility for the evaluation of regional liver function impairment following transcatheter arterial chemoembolization. Oncol Lett 9:1191–1196PubMed Xiao YD, Paudel R, Liu H, et al. (2015) Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging: a potential utility for the evaluation of regional liver function impairment following transcatheter arterial chemoembolization. Oncol Lett 9:1191–1196PubMed
78.
go back to reference Shinagawa Y, Sakamoto K, Fujimitsu R, et al. (2010) Pseudolesion of the liver observed on gadoxetate disodium-enhanced magnetic resonance imaging obtained shortly after transarterial chemoembolization for hepatocellular carcinoma. Jpn J Radiol 28:483–488CrossRefPubMed Shinagawa Y, Sakamoto K, Fujimitsu R, et al. (2010) Pseudolesion of the liver observed on gadoxetate disodium-enhanced magnetic resonance imaging obtained shortly after transarterial chemoembolization for hepatocellular carcinoma. Jpn J Radiol 28:483–488CrossRefPubMed
79.
go back to reference Powerski MJ, Scheurig-Munkler C, Hamm B, Gebauer B (2014) Impaired hepatic Gd-EOB-DTPA enhancement after radioembolisation of liver malignancies. J Med Imaging Radiat Oncol 58:472–480PubMed Powerski MJ, Scheurig-Munkler C, Hamm B, Gebauer B (2014) Impaired hepatic Gd-EOB-DTPA enhancement after radioembolisation of liver malignancies. J Med Imaging Radiat Oncol 58:472–480PubMed
80.
go back to reference Mu H, Ariizumi S, Katagiri S, Egawa H, Yamamoto M (2014) An extended dysfunctional area in the congestive area of the remnant liver after hemi-hepatectomy with middle hepatic vein resection for liver cancers evaluated on the gadoxetic acid disodium-enhanced magnetic resonance imaging. J Hepatobiliary Pancreat Sci 21:64–71CrossRefPubMed Mu H, Ariizumi S, Katagiri S, Egawa H, Yamamoto M (2014) An extended dysfunctional area in the congestive area of the remnant liver after hemi-hepatectomy with middle hepatic vein resection for liver cancers evaluated on the gadoxetic acid disodium-enhanced magnetic resonance imaging. J Hepatobiliary Pancreat Sci 21:64–71CrossRefPubMed
81.
go back to reference Okamoto D, Nishie A, Asayama Y, et al. (2014) Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced MR finding of radiation-induced hepatic injury: relationship to absorbed dose and time course after irradiation. Magn Reson Imaging 32:660–664CrossRefPubMed Okamoto D, Nishie A, Asayama Y, et al. (2014) Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced MR finding of radiation-induced hepatic injury: relationship to absorbed dose and time course after irradiation. Magn Reson Imaging 32:660–664CrossRefPubMed
Metadata
Title
Non-focal liver signal abnormalities on hepatobiliary phase of gadoxetate disodium-enhanced MR imaging: a review and differential diagnosis
Authors
Alessandro Furlan
Amir A. Borhani
Matthew T. Heller
Robinson K. Yu
Mitchell E. Tublin
Publication date
01-07-2016
Publisher
Springer US
Published in
Abdominal Radiology / Issue 7/2016
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-016-0685-z

Other articles of this Issue 7/2016

Abdominal Radiology 7/2016 Go to the issue

Classics in Abdominal Imaging

The String of Pearls Sign

Commentary

Book Review

Classics in Abdominal Imaging

Colon cutoff sign

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.